Company intelligence
Innoblative
Our core values are to drive innovation, improve patient experience, and impact economics.
About Innoblative
Innoblative is a private medical device company addressing clinical unmet needs for patients with breast cancer and other soft tissue diseases. We are developing advanced energy-based surgical solutions to help improve the way surgeons coagulate and ablate soft tissue to achieve better care for patients. Innoblative has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the company’s SIRA® RFA Electrosurgical Device. The SIRA® device is investigational for use in BCS and is not yet available for sale in the United States. The SIRA® device is cleared for intraoperative coagulation and ablation of soft tissue.
Verified activity
Signals from Innoblative
3 published signals
Presence & Recognition
Innoblative is working alongside Serumwerk Bernburg and MontesJura on EmboLog S, degradable starch microspheres for short term embolization in unresectable liver tumours.
Reported by Nicola Capaldi
Presence & Recognition
Innoblative announced that there are exciting new projects taking shape at N:MED alongside familiar ones gathering pace again.
Reported by Nicola Capaldi
Presence & Recognition
Innoblative's CEO Richard Stark will attend LSI Europe 26 from September 28 to October 1, 2026, at the Grand Hyatt Barcelona.
Reported by Innoblative